HDL Therapeutics competitorsClear all
HDL Therapeutics's top competitors include BioCardia, FIRE1, ElectroCore and ReShape Lifesciences.
| Save Comparison |  HDL Therapeutics HDL Therapeutics is a company that develops medical devices for the treatment of coronary atherosclerosis. |  ElectroCore ElectroCore develops neuromodulation therapies for the non-invasive treatment of diseases and disorders. |  ReShape Lifesciences ReShape Lifesciences, a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. | ||
Founding Date | Founding Date 2009 | Founding Date 2002 | Founding Date N/A | Founding Date 2005 | Founding Date 2002 |
Type | Type Private | Type Private | Type Private | Type Public | Type Public |
Tags | |||||
Locations | Locations Vero Beach, US HQ | Locations San Carlos, US HQ | Locations Glasnevin, IE HQ Dublin, IE | Locations Bernards, US HQ Parksville, CA Geretsried, DE Hamburg, DE Yeadon, GB | Locations San Clemente, US HQ San Clemente, US |
Employees | Employees 7 | Employees 2713% increase | Employees 36 | Employees 5144% decrease | Employees 4348% decrease |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 120.9 m | Valuation ($) 38.3 m |
Twitter followers | Twitter followers N/A | Twitter followers N/A | Twitter followers N/A | Twitter followers 1.8 k | Twitter followers 402 |
Alexa Website Rank | Alexa Website Rank 222186 | Alexa Website Rank 257929 | Alexa Website Rank 591409 | Alexa Website Rank 281232 | Alexa Website Rank 421170 |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $710k (FY, 2019) | Revenue (est.) N/A | Revenue (est.) $2.4m (FY, 2019) | Revenue (est.) $15.1m (FY, 2019) |
Cost of goods | Cost of goods N/A | Cost of goods $358k (FY, 2019) | Cost of goods N/A | Cost of goods $1.2m (FY, 2019) | Cost of goods $5.8m (FY, 2019) |
Gross profit | Gross profit N/A | Gross profit $352k (FY, 2019) | Gross profit N/A | Gross profit $1.2m (FY, 2019) | Gross profit $9.3m (FY, 2019) |
Net income | Net income N/A | Net income ($14.7m) (FY, 2019) | Net income N/A | Net income ($45.1m) (FY, 2019) | Net income ($74.2m) (FY, 2019) |
Funding | |||||
Latest funding round | Latest funding round $ 3m (over 1 year ago) | Latest funding round $ 7.4m (over 12 years ago) | Latest funding round $ 7.5m (almost 5 years ago) | Latest funding round N/A | Latest funding round N/A |
Total funding raised | Total funding raised $ 7.4m | Total funding raised N/A | Total funding raised $ 7.5m | Total funding raised $ 127m | Total funding raised N/A |
For sources of this data, please see the company profile
View company profiles
BioCardia
HQ
San Carlos, US
Employees
27↑ 13% increase
BioCardia is a clinical-stage regenerative medicine company.
View company
FIRE1
HQ
Glasnevin, IE
Employees
36
FIRE1 focuses on developing novel remote monitoring devices.
View companyElectroCore
HQ
Bernards, US
Employees
51↓ 44% decrease
ElectroCore develops neuromodulation therapies for the non-invasive treatment of diseases and disorders.
View companyReShape Lifesciences
HQ
San Clemente, US
Employees
43↓ 48% decrease
ReShape Lifesciences, a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders.
View company